DOCSLIB.ORG

Drug Tariff Part II June 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Tariff Part II June 2017 06/2017 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Contractors who have not received discount in respect of the following products need not endorse the prescription. The prescription price reimbursement will have no discount deduction applied. GROUP ITEMS Cold Chain Storage (ALL) Controlled Drugs in schedules 1, 2 and 3 of the Misuse of Drugs Regulations 2001 Cytotoxic or Cytostatic items (ALL) Immunoglobulins (ALL) Insulins for Injection (ALL) Vaccines and Antisera (ALL) Unlicensed medicines not listed in Part VIIIB where the product has been sourced from a supplier holding a MHRA specials or importers licence (prescriptions must be endorsed with invoice price less discount/rebate) INDIVIDUAL ITEMS Acetic acid 33% liquid Acetic acid dilute 420microlitres/5ml oral solution sugar free Acetic acid glacial Aclasta 5mg/100ml infusion bottles Acumor XL 16mg capsules Acumor XL 24mg capsules A-CYS 600mg capsules A-CYS 600mg tablets Adcirca 20mg tablets Add Ins oral powder 18.2g sachets Addiphos solution for infusion 20ml vials Adoport capsules (ALL) Advagraf 1mg modified-release capsules Advagraf 3mg modified-release capsules Advagraf 5mg modified-release capsules Alicalm oral powder Alimemazine 30mg/5ml oral solution Alprostadil 20microgram powder and solvent for solution for injection vials Amitiza 24microgram capsules Ammonaps 500mg tablets Ammonaps 940mg/g granules Ammonia solution strong Ammonium chloride powder Ampicillin 500mg powder for solution for injection vials Anise water concentrated APO-go PEN 30mg/3ml solution for injection APO-go PFS 50mg/10ml solution for infusion pre-filled syringes APO-go solution for injection ampoules (ALL) Apomorphine 30mg/3ml solution for injection pre-filled disposable devices Apomorphine 50mg/10ml solution for infusion pre-filled syringes Apomorphine 50mg/5ml solution for injection ampoules Arimidex 1mg tablets Arixtra solution for injection pre-filled syringes (ALL) Arnica tincture Aromasin 25mg tablets Aspirin 300mg suppositories Atomoxetine capsules (ALL) Atripla 600mg/200mg/245mg tablets Baraclude tablets (ALL) Benzocaine powder Benzoic acid powder Benzoin compound tincture Benzoin tincture Benzyl benzoate 25% application Benzyl benzoate crystals Berinert 500unit powder and solvent for solution for injection vials Betaferon 300microgram powder and solvent for solution for injection vials 10 06/2017 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Bismuth subnitrate powder Bramox 5mg tablets Bricanyl 2.5mg/5ml solution for injection ampoules Briviact 100mg tablets Briviact 10mg/ml oral solution Briviact 25mg tablets Briviact 50mg tablets Briviact 50mg/5ml solution for injection vials Briviact 75mg tablets Bromocriptine 2.5mg tablets Bronchitol 40mg inhalation powder capsules with two devices Budesonide 1mg/2ml nebuliser liquid unit dose vials Budesonide 500micrograms/2ml nebuliser liquid unit dose vials Bumetanide 1mg/5ml oral solution sugar free Cabaser 1mg tablets Cabaser 2mg tablets Caffeine citrate powder Caffeine citrate 10mg/1ml solution for injection ampoules Calamine and coal tar ointment Calogen Extra emulsion Camphor racemic powder Camphor water concentrated Capexion 0.5mg capsules Capexion 1mg capsules Capimune 100mg capsules Capimune 50mg capsules Capreomycin 1g powder for solution for injection vials Capsicum tincture Capsorin 100mg capsules Cardamom compound tincture Casodex tablets (ALL) Caverject 20microgram powder and solvent for solution for injection vials CellCept 1g/5ml oral suspension CellCept 250mg capsules CellCept 500mg tablets Celsentri tablets (ALL) Cerezyme 400 unit powder for solution for infusion vials Cetrimide powder Chloral hydrate crystals Chloramphenicol 250mg capsules ChloraPrep solution 26ml applicators ChloraPrep with Tint solution 26ml applicators Chlorhexidine gluconate 0.5% solution Chlorhexidine gluconate 4% solution Chlorocresol powder Chloroform and morphine tincture Chloroform liquid Chloroform spirit Chloroform water concentrated Cholestagel 625mg tablets Cimzia 200mg/1ml solution for injection pre-filled syringes Cinacalcet tablets (ALL) Ciprofibrate 100mg tablets Citric acid monohydrate powder Citronella oil liquid Clarithromycin 500mg powder for solution for infusion vials Clexane 300mg/3ml solution for injection multidose vials Clexane Forte solution for injection pre-filled syringes (ALL) Clexane 40mg/0.4ml solution for injection pre-filled syringes Clexane 60mg/0.6ml solution for injection pre-filled syringes Clexane 80mg/0.8ml solution for injection pre-filled syringes 11 Part II 06/2017 REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Clexane 100mg/1ml solution for injection pre-filled syringes Clobazam 10mg/5ml oral suspension sugar free Clobazam 5mg/5ml oral suspension sugar free Clove oil liquid Clozaril 100mg tablets Coal tar solution Coal tar solution strong Co-codaprin 8mg/400mg dispersible tablets Co-danthramer 25mg/200mg/5ml oral suspension sugar free Colesevelam 625mg tablets Colistimethate 1million unit powder for solution for injection vials Colobreathe 1,662,500unit inhalation powder capsules Combivir 150mg/300mg tablets Complete Amino Acid Mix Powder Concord 693 250mg capsules Copaxone 20mg/1ml solution for injection pre-filled syringes Copegus tablets (ALL) Copper sulfate pentahydrate powder CosmoFer 500mg/10ml solution for injection ampoules Crystal violet powder BP 1980 Cystadane oral powder Cystagon capsules (ALL) Cystine500 oral powder sachets Dalteparin sodium 10,000units/0.4ml solution for injection pre-filled syringes Dalteparin sodium 10,000units/1ml solution for injection pre-filled syringes Dalteparin sodium 12,500units/0.5ml solution for injection pre-filled syringes Dalteparin sodium 15,000units/0.6ml solution for injection pre-filled syringes Dalteparin sodium 18,000units/0.72ml solution for injection pre-filled syringes Dalteparin sodium 5,000units/0.2ml solution for injection pre-filled syringes Dalteparin sodium 7,500units/0.3ml solution for injection pre-filled syringes Dapsone tablets (ALL) Decapeptyl SR powder and solvent for suspension for injection vials (ALL) Deferiprone 100mg/ml oral solution sugar free Deferiprone 1g tablets Demeclocycline 150mg capsules Demorem 4mg/5ml oral solution Descovy 200mg/10mg tablets Descovy 200mg/25mg tablets Denzapine 100mg tablets Desferal 500mg powder for solution for injection vials Desferrioxamine 2g powder for solution for injection vials Desmospray 10micrograms/dose nasal spray Desmospray 2.5micrograms/dose nasal spray Deximune 100mg capsules Deximune 50mg capsules Diacomit capsules (ALL) Diacomit oral powder sachets (ALL) Dialamine powder Diethylstilbestrol tablets (ALL) Dificlir 200mg tablets Diflucan 200mg capsules Diflucan 200mg/5ml oral suspension Diloxanide 500mg tablets Dithranol powder Donepezil orodispersible tablets (ALL) EAA Supplement oral powder 12.5g sachets Easiphen liquid E-B2 50mg capsules Edurant 25mg tablets Elemental 028 Extra liquid Elemental 028 Extra powder 12 06/2017 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Elive Cod Liver Oil 1000mg capsules Elmino XL 16mg capsules Emsogen powder Emtriva 200mg capsules Energivit powder Enoxaparin sodium 40mg/0.4ml solution for injection pre-filled syringes Enoxaparin sodium 60mg/0.6ml solution for injection pre-filled syringes Enoxaparin sodium 80mg/0.8ml solution for injection pre-filled syringes Enoxaparin sodium 100mg/1ml solution for injection pre-filled syringes Enoxaparin sodium 120mg/0.8ml solution for injection pre-filled syringes Enoxaparin sodium 150mg/1ml solution for injection pre-filled syringes EN-Selenium 200microgram tablets Enshake oral powder 96.5g sachets banana Ensure Plus Commence liquid Ensure TwoCal liquid EN-Taurine 500mg capsules Entocort 2mg/100ml enema EpiPen Jr. 150micrograms/0.3ml (1 in 2,000) solution for injection auto-injectors Epivir 300mg tablets Ethanol 70% duty paid Ethanol 90% including duty Ethanol Absolute Duty Paid Ethosuximide 250mg capsules Ether solvent Ethinylestradiol 10mcg tablets Ethinylestradiol 1mg tablets Ethinylestradiol 50mcg tablets Eucalyptus oil liquid Eviplera 200mg/25mg/245mg tablets Exjade dispersible tablets (ALL) Extavia 300microgram powder and solvent for solution for injection vials Famciclovir 250mg tablets Famciclovir 500mg tablets Fampyra 10mg modified-release tablets Femara 2.5mg tablets Ferinject 100mg/2ml solution for injection vials Ferinject 500mg/10ml solution for injection vials Ferric chloride solution Ferriprox 1000mg tablets Ferriprox 100mg/ml oral solution Ferrous sulfate heptahydrate powder Fibrovein 0.5% solution for injection 2ml ampoules Firdapse 10mg tablets Firmagon powder and solvent for solution for injection vials (ALL) Flexible collodion methylated Flixotide 2mg/2ml nebules Flucloxacillin 1g powder for solution for injection vials Flucloxacillin 500mg powder for solution for injection vials Fluconazole 200mg/5ml oral suspension Fluticasone 250micrograms/dose / Formoterol 10micrograms/dose inhaler CFC free Flutiform 250micrograms/dose / 10micrograms/dose inhaler Formaldehyde solution Fortini liquid Fortini Multi Fibre liquid Fortisip Compact Starter Pack liquid Fortum 1g powder for solution for injection vials Fortum
Load more

Recommended publications
  • Bonviva, INN- Ibandronic Acid
    European Medicines Agency London, 1 September 2005 Doc.Ref.: EMEA/278873/2005 Bonviva International Nonproprietary Name: Ibandronic acid Following the procedure EMEA/H/C/501/X/01 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: [email protected] http://www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged 1 SCIENTIFIC DISCUSSION 1.1 Introduction and rationale The MAH submitted an extension application under Annex II, point 2 iii to Commission Regulation (EC) No 1085/2003 to request the approval of a 150 mg tablet as a monthly dosing regimen of ibandronate only for the indication of “treatment of osteoporosis in postmenopausal women, in order to reduce the risk of vertebral fractures”. This claim is based on the results of a phase III study MOBILE (BM16549) comparing 100 and 150 mg once monthly to 2.5 mg once daily. Due to the inconveniences associated with intake of oral bisphosphonates (i.e. fasting conditions, frequent upper gastrointestinal intolerance) that may result in poor compliance, it was considered desirable to develop a more convenient drug formulation. Hence a 150 mg once monthly oral regimen is expected to offer greater convenience to postmenopausal women when compared to the currently approved 2.5mg once daily tablet. The development programme No new pre-clinical pharmacodynamic and pharmacokinetic studies have been performed in addition to those included in the previous submission for ibandronate 2.5 mg daily oral tablets.
    [Show full text]
  • CCA Senior Care Options Formulary
    Commonwealth Care Alliance Senior Care Option HMO SNP 2021 List of Covered Drugs Formulary 30 Winter Street • Boston, MA 02108 PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN This formulary was updated on 08/01/2021. For more recent information or other questions, please contact Senior Care Options Program (HMO SNP) Member Services, at 1-866-610-2273 or, for TTY users, 711, 8 a.m. – 8 p.m., 7 days a week, or visit www.commonwealthcaresco.org. HPMS Approved Formulary File Submission ID 00021589, Version Number 13 Senior Care Options Program (HMO SNP) 2021 Formulary (List of Covered Drugs) PLEASE READ: THIS DO CUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN HPMS Approved Formulary File Submission ID 00021589, Version Number 13 Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us”, or “our,” it means Commonwealth Care Alliance. When it refers to “plan” or “our plan,” it means 2021 Senior Care Options Program. This document includes list of the drugs (formulary) for our plan which is current as of 08/01/2021. This formulary document applies to all SCO members. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy n etwork, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year.
    [Show full text]
  • Bisphosphonate Use in Patients with Breast Cancer
    Bisphosphonate use in patients with breast cancer Information for patients, relatives and carers For more information, please contact: Medicines Information Email: [email protected] York Hospital Medicines Information Tel: 01904 725960 Page 2 Contents Page Why have I been given this leaflet? ............................... 4 How is the treatment given? .......................................... 4 How long will I need to take the treatment for? .............. 6 Can I take other medicines at the same time? ............... 6 Who will prescribe the medication? ............................... 7 What if I am already on bisphosphonate treatment? ...... 7 Bisphosphonates are not licensed for reducing the risk of breast cancer recurrence. What does this mean? ...... 8 Are there any side effects? ............................................ 9 What is osteonecrosis? ............................................... 10 Are there any signs and symptoms I should look out for during treatment? ........................................................ 11 How can I decrease the risk of developing osteonecrosis of the jaw? ................................................................... 12 What do I need to do before starting treatment? .......... 13 Will I require any monitoring, or blood tests? ............... 14 Should I stop taking the bisphosphonate? ................... 14 Tell us what you think of this leaflet ............................. 15 Teaching, training and research ................................... 15 Patient Advice and Liaison Service (PALS) .................. 15 Page 3 Why have I been given this leaflet? You have been given this leaflet because you are going to be treated with a bisphosphonate medicine (zoledronic acid and/or ibandronic acid). In post-menopausal women, with early breast cancer, these drugs have been shown to reduce the risk of the disease recurring and increase length of life. How is the treatment given? The treatment will usually be provided as an oral tablet of ibandronic acid (one 50mg tablet taken once daily).
    [Show full text]
  • Active Moiety Name FDA Established Pharmacologic Class (EPC) Text
    FDA Established Pharmacologic Class (EPC) Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for [indication(s)].” For Active Moiety Name each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13. .alpha.
    [Show full text]
  • Illness Code A
    Long Term Illness (LTI) Scheme: Reference Guide as to what is covered in the Health Service Executive for each of the 16 scheduled LTI illnesses. (January 2021) Illness Code C: Cerebral Palsy Antibiotics 1. Doxycycline J01AA02 2. Lymecycline J01AA04 3. Minocycline J01AA08 4. Ampicillin J01CA01 5. Amoxicillin J01CA04 6. Azlocillin J01CA09 7. Benzylpenicillin J01CE01 8. Phenoxymethylpenicillin J01CE02 9. Flucloxacillin J01CF05 10. Amoxicillin & Enzyme Inhibitor J01CR02 11. Cefalexin J01DB01 12. Cefuroxime J01DC02 13. Cefaclor J01DC04 14. Ceftazidime J01DD02 15. Ceftriaxone J01DD04 16. Cefixime J01DD08 17. Cefpodoxime J01DD13 18. Trimethoprim J01EA01 19. Sulfamethoxazole & Trimethoprim J01EE01 20. Erythromycin J01FA01 21. Clarithromycin J01FA09 22. Azithromycin J01FA10 23. Clindamycin J01FF01 24. Gentamicin J01GB03 25. Amikacin J01GB06 26. Ofloxacin J01MA01 27. Ciprofloxacin J01MA02 28. Levofloxacin J01MA12 29. Moxifloxacin J01MA14 30. Vancomycin J01XA01 31. Teicoplanin J01XA02 32. Colistin J01XB01 33. Fusidic Acid J01XC01 34. Nitrofurantoin J01XE01 Muscle relaxants 1. Baclofen M03BX01 2. Tizanidine M03BX02 3. Dantrolene M03CA01 Anticonvulsants (including Benzodiazepines used for this purpose) 1. Phenobarbital N03AA02 2. Primidone N03AA03 page 1 3. Phenytoin N03AB02 4. Ethosuximide N03AD01 5. Clonazepam N03AE01 6. Carbamazepine N03AF01 7. Oxcarbazepine N03AF02 8. Rufinamide N03AF03 9. Eslicarbazepine N03AF04 10. Valproic Acid N03AG01 11. Vigabatrin N03AG04 12. Tiagabine N03AG06 13. Lamotrigine N03AX09 14. Topiramate N03AX11 15. Gabapentin N03AX12 16. Levetiracetam N03AX14 17. Zonisamide N03AX15 18. Pregabalin N03AX16 19. Lacosamide N03AX18 20. Retigabine N03AX21 21. Perampanel N03AX22 22. Diazepam (Rectal) N05BA01 23. Clobazam N05BA09 24. Midazolam N05CD08 25. Acetazolamide S01EC01 Anxiolytics 1. Diazepam N05BA01 2. Chlordiazepoxide N05BA02 3. Lorazepam N05BA06 4. Bromazepam N05BA08 5. Clobazam N05BA09 6. Prazepam N05BA11 7. Alprazolam N05BA12 Hypnotics 8.
    [Show full text]
  • ATC/DDD Classification
    WHO Drug Information Vol. 31, No. 4, 2017 ATC/DDD classification The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit are tools for exchanging and comparing data on drug use at international, national or local levels. The ATC/ DDD system has become the gold standard for international drug utilization research. It is maintained by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo, Norway. Visit www.whocc.no/ for more information. ATC/DDD classification (temporary) The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in October 2017. Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology before 1 February 2018. If no objections are received before this date, the new ATC codes and DDDs will be considered final and included in the January 2019 version of the ATC/DDD Index. New ATC 5th level codes ATC level name/INN ATC code ambrisentan and tadalafil C02KX52 atazanavir and ritonavir J05AR23 atezolizumab L01XC32 avelumab L01XC31 caplacizumab B01AX07 cefteram J01DD18 cladribine1 L04AA40 clenbuterol and ambroxol R03CC63 crisaborole D11AH06 crofelemer A07XA06 cytarabine and daunorubicin L01XY01 dacomitinib L01XE47 dapivirine G01AX17 delafloxacin J01MA23 doxepin D04AX01 emapalumab L04AA39 enasidenib L01XX59 encorafenib L01XE46 Continued 629 ATC/DDD classification WHO Drug Information Vol. 31, No. 4, 2017
    [Show full text]
  • Position Paper American Association of Oral and Maxillofacial Surgeons
    saving faces|changing lives® Position Paper American Association of Oral and Maxillofacial Surgeons Medication-Related Osteonecrosis of the Jaw—2014 Update Special Committee on Medication- Introduction Related Osteonecrosis of the Jaws: The Special Committee recommends changing the Salvatore L. Ruggiero, DMD, MD, Clinical nomenclature of bisphosphonate-related osteonecrosis of Professor, Division of Oral and Maxillofacial the jaw (BRONJ). The Special Committee favors the term Surgery, Stony Brook School of Dental Medicine, medication-related osteonecrosis of the jaw (MRONJ). Hofstra North Shore-LIJ School of Medicine, The change is justifed to accommodate the growing New York Center for Orthognathic and Maxillo- number of osteonecrosis cases involving the maxilla and facial Surgery, Lake Success, NY mandible associated with other antiresorptive (denosumab) and antiangiogenic therapies. Thomas B. Dodson, DMD, MPH, Professor and Chair, Associate Dean for Hospital Affairs, MRONJ adversely affects the quality of life, produc- University of Washington School of Dentistry, ing signifcant morbidity. Strategies for management of Department of Oral and Maxillofacial Surgery, patients with, or at risk for, MRONJ were set forth in the Seattle, WA American Association of Oral and Maxillofacial Sur- geons (AAOMS) updated Position Paper on Bisphospho- John Fantasia, DDS, Chief, Division of Oral nate-Related Osteonecrosis of the Jaws and approved by Pathology, Hofstra North Shore-LIJ School of the Board of Trustees in 2009.1 The Position Paper was Medicine , New Hyde Park, NY developed by a Special Committee appointed by the Board Reginald Goodday, Professor, Department of Oral and composed of clinicians with extensive experience in and Maxillofacial Sciences, Dalhousie University, caring for these patients and basic science researchers.
    [Show full text]
  • Recommendations from York and Scarborough Medicines Commissioning Committee September 2017
    Recommendations from York and Scarborough Medicines Commissioning Committee September 2017 Drug name Indication Recommendation, rationale and place in therapy RAG status Potential full year cost impact 1 TA463: Cabozantinib for previously Recommended as an option for treating advanced Red No cost impact to CCGs as NHS treated advanced renal cell renal cell carcinoma in adults after VEGF-targeted England commissioned. carcinoma therapy, only if company provides it with discount agreed in the PAS. 2 TA464: Bisphosphonates for Oral bisphosphonates (alendronic acid, ibandronic acid All drugs Low/no cost impact expected. It is not treating osteoporosis and risedronate sodium) are recommended as options listed in the expected that practice will change for treating osteoporosis in adults only if: guidance are substantially as a result of this the person is eligible for risk assessment as already on guidance. defined in NICE's guideline on osteoporosis and formulary as green (oral) the 10‑year probability of osteoporotic fragility or red (IV) for fracture is at least 1%. osteoporosis Intravenous bisphosphonates (ibandronic acid and zoledronic acid) are recommended as options for treating osteoporosis in adults only if: the person is eligible for risk assessment as defined in NICE's guideline on osteoporosis and the 10‑year probability of osteoporotic fragility fracture is at least 10% or the 10‑year probability of osteoporotic fragility fracture is at least 1% and the person has difficulty taking oral bisphosphonates (alendronic acid, ibandronic acid or risedronate sodium) or these drugs are contraindicated or not tolerated. 3 TA465: Olaratumab in combination Olaratumab, in combination with doxorubicin, is Red No cost impact to CCGs as NHS with doxorubicin for treating recommended for use within the Cancer Drugs Fund England commissioned.
    [Show full text]
  • “Wherever the Art of Medicine Is Loved, There Is Also Love of Humanity" Hipócrates ABOUT US
    “Wherever the art of Medicine is loved, there is also love of Humanity" Hipócrates ABOUT US CATENA GROUP provides complete and vertical services, we act as a key link for all our clients as well as offering to obtain various benefits in their purchases. Such as simplification of procedures through the know-how of our company, relationships and experience in the different sectors EXPLANATION & PHILOSOPHY that we are specialized in, these are just some of the unique CATENA FROM LATIN, CATENA, /ka'te:.na/ advantages on collaborating with us. Circular object formed by interlaced links. Intangible bond that unites people. Succession of related facts or phenomena. Consequently, we are able to satisfy 100% of our customer‘s needs through our networks of contacts, control, dedication and engagement in every operation. CATENA MEDICAL SERVICES operates We provide all of the services to facilitate Subsequently, our work with more than 778 mainly as a purchasing center (not as a our client’s work with first level laboratories references of generic medicines (including distributor) for Governments and State or from countries such as France, Germany, Food Supplements, Vitamins, Women's Private Companies. Greece, Italy, Spain, etc. We assist them by hygiene products, etc.) and more than 30 handling the negotiations in order to top-level laboratories, one of the key unique We are specialists in providing solutions to achieve their target prices and orders, advantages of working with us is our ability our client’s requirements. simplify document management and to adapt the research of our team, in order provide logistics and legal support if to provide the most interesting products required, etc.
    [Show full text]
  • Brand to Generic Switches
    Brand to Generic switches Original Product Strength Pack Size Cost per Change to Pack size Cost per Savings per Notes Annual month month month savings/ pack 15mg £25.83 £1.63 £24.20 £314.60 Actos® tablets 30mg 28 £35.89 Pioglitazone tablets 28 £1.90 £33.99 £441.87 45mg £39.55 £2.62 £36.93 £480.09 2mg £3.58 £1.13 £2.45 £127.40 7 7 4mg £3.88 £0.86 £3.02 £157.04 Amias® tablets 8mg £9.89 Candesartan tablets £1.53 £8.36 £108.68 16mg 28 £12.72 28 £1.57 £11.15 £144.95 32mg £16.13 £1.97 £14.16 £184.08 75mg £9.69 £3.07 £6.62 £86.06 Aprovel® tablets 150mg 28 £11.84 Irbesartan tablets 28 £5.78 £6.06 £78.78 300mg £15.93 £5.84 £10.09 £131.17 10mg £51.13 Leflunomide tablets 10mg £4.79 £46.34 £556.08 Arava® tablets 30 30 20mg £61.36 Leflunomide tablets 20mg £4.83 £56.53 £678.36 30mg £13.99 £4.68 £9.31 £121.03 60mg £20.11 £3.03 £17.08 £222.04 Arcoxia® tablets 28 Etoricoxib tablets 28 90mg £22.96 £2.99 £19.97 £259.61 120mg £24.11 £12.35 £11.76 £1,328.88 5mg £59.85 £1.38 £58.47 £760.11 Aricept® tablets 28 Donepezil tablets 28 10mg £83.89 £2.42 £57.43 £746.59 5mg £59.85 Donepezil orodispersible sugar free £9.38 £50.47 £656.11 Aricept Evess® tablets 28 28 10mg £83.89 tablets £10.43 £73.46 £954.98 Arimidex® tablets 1mg 28 £68.56 Anastrazole tablets 28 £1.85 £66.71 £867.23 Aromasin® tablets 25mg 30 £88.80 Exemestane tablets 30 £33.52 £55.28 £663.36 5mg £96.04 £1.38 £94.66 £1,230.58 10mg £96.04 £1.57 £94.47 £1,228.11 Arpoya® tablets 28 Aripiprazole tablets 28 15mg £96.04 £1.74 £94.30 £1,225.90 30mg £192.08 £13.57 £178.51 £2,320.63 Audmonal® capsules £14.80
    [Show full text]
  • CCA Senior Care Options Formulary
    Commonwealth Care Alliance Senior Care Option HMO SNP 2021 List of Covered Drugs Formulary 30 Winter Street • Boston, MA 02108 PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN This formulary was updated on 06/01/2021. For more recent information or other questions, please contact Senior Care Options Program (HMO SNP) Member Services, at 1-866-610-2273 or, for TTY users, 711, 8 a.m. – 8 p.m., 7 days a week, or visit www.commonwealthcaresco.org. HPMS Approved Formulary File Submission ID 00021589, Version Number 11 Senior Care Options Program (HMO SNP) 2021 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN HPMS Approved Formulary File Submission ID 00021589, Version Number 11 Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us”, or “our,” it means Commonwealth Care Alliance. When it refers to “plan” or “our plan,” it means 2021 Senior Care Options Program. This document includes list of the drugs (formulary) for our plan which is current as of 06/01/2021. This formulary document applies to all SCO members. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year.
    [Show full text]
  • Information for the Patient <Ibandronic Acid 50 Mg Film-Coated Tablets>
    NL/H/1834/001-002/DCIbandronic acid 50 mg PL, NL1834 Ibandronic acid 50 mg / 150 mg film-coated tablets Submission: 12/2016 Package leaflet: Information for the patient <Ibandronic acid 50 mg film-coated tablets> Ibandronic acid Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What <Ibandronic acid 50 mg> is and what it is used for. 2. What you need to know before you take <Ibandronic acid 50 mg>. 3. How to take <Ibandronic acid 50 mg>. 4. Possible side effects. 5. How to store <Ibandronic acid 50 mg> 6. Contents of the pack and other information. 1. What <Ibandronic acid 50 mg> is and what it is used for <Ibandronic acid 50 mg> contains the active substance ibandronic acid. This belongs to a group of medicines called bisphosphonates. <Ibandronic acid 50 mg> is used in adults and prescribed to you if you have breast cancer that has spread to your bones (called bone “metastases”). It helps to prevent your bones from breaking (fractures).
    [Show full text]